期刊文献+

成年人免疫性血小板减少症治疗进展 被引量:1

原文传递
导出
摘要 免疫性血小板减少症(ITP)是一种自身免疫性疾病,经典的治疗手段有糖皮质激素、免疫抑制剂和脾切除,但仍有约1/3的患者治疗无效或者复发。但随着对其发病机制研究的深入,新的治疗方案和新药也不断问世,治疗效果也显著进步。血小板生成素可以促进PLT再生,有效提高患者PLT的水平;利妥昔单抗能够通过抑制B淋巴细胞、减少抗PLT抗体的产生,具有很好的疗效和安全性。大剂量糖皮质激素、酶酚酸酯、环孢素等已成为ITP治疗的新选择。
出处 《国际输血及血液学杂志》 CAS 2012年第6期539-542,共4页 International Journal of Blood Transfusion and Hematology
基金 山东省科技攻关计划项目(2009GG10002020)、山东省自然科学基金.重点项目(Z2008C08)、山东省医药卫生计划项目(2007HZ046)、山东省教育厅科技计划项目(J06L69)
  • 相关文献

参考文献27

  • 1Rodeghiero F, Slasi R, Germheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an internation working group. Blood, 2009, 113 (11): 2386-2398.
  • 2Stasil R, Evangelista mL. Stipa E, et al. Idiopathic thrombocytopenic purpra , current concepts in pathophysiology and management. Thtomb Haernost , 2008, 990): 4-13.
  • 3成人特发性血小板减少性紫癜诊断治疗专家共识[J].中华血液学杂志,2009,30(9):647-648. 被引量:81
  • 4Stasi R. Immune thrombosytopenic purpura: the .. treatment paradigm. EuroJ Haernatol , Z009, 8Z(71): 13-19.
  • 5Borst F, Keuning JJ, van Hulsteijn H et al. High-dose dose dexamethasone as a first-and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol, 2004, 83 OZ): 764-768.
  • 6Zhou Z, Chen Z, Li H, et al. BAFF and BAFF-R of peripheral blood and spleen mononuelear cells in idiopathic thrombocytopenic purpura. Autoimmunity, 2009, 42(2): 112-119.
  • 7Yu J, Heck S, Patel V, et al. Defective circulating CDZ5 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood,2008, 112(4): 1325-1328.
  • 8王春燕,朱效娟,侯明,石艳,彭军,孙建芝,秦平,冀学斌,王琳,王谦.大剂量地塞米松对特发性血小板减少性紫癜患者B细胞活化因子及调节性T细胞的影响[J].中华血液学杂志,2010,31(3):164-167. 被引量:16
  • 9Shan NN, Zhu XJ, Wang Q, et al. High-dose dexamethasone regulates interleukin-18 and interleukin-18 binding protein in idiopathic thrombocytopenic purpura. Haernatologica , 2009, 94 (11): 1603-1607.
  • 10Liu B, Zhao H, Poon MC, et al. Abnormality of CIM+CD25+ regulatory T ceHs in idiopathic thrornbo- cytopenic purpura. Eur ] Haematol, 2007, 78(2): 139-143.

二级参考文献30

  • 1侯明,秦平.欧美国家特发性血小板减少性紫癜诊治意见介绍[J].中华血液学杂志,2005,26(3):191-192. 被引量:17
  • 2秦平,陈峰,张春青,彭军,陈学良,侯明.大剂量地塞米松治疗慢性特发性血小板减少性紫癜的疗效观察[J].中华内科杂志,2005,44(6):451-452. 被引量:46
  • 3中华医学会血液学学会血栓与止血学组.几种出血性疾病诊断(及疗效)标准的修订[J].中华血液学杂志,1995,16:331-331.
  • 4Schiemann B,Gommerman JL,Vora K,et al.An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway.Science,2001,293:2111-2114.
  • 5O'Connor BP,Raman VS,Erickson LD,et al.BCMA is essential for the survival of long-lived bone marrow plasma cells.J Exp Med.2004.199:91-97.
  • 6Emmerich F,Bal G,Barakat A,et al.High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura.Br J Haematol,2007,136:309-314.
  • 7Yu J,Heck S,Patel V,et al.Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura.Blood,2008,112:1325-1328.
  • 8Rodeghiero F,Stasi R,Gernsheimer T,et al.Standardization of terminology,definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an intemational working group.Blood,2009,113:2386-2393.
  • 9Stohl W,Metyas S,Tan SM,et al.B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus:longitudinal observations.Arthritis Rheum.2003,48:3475-3486.
  • 10Seyler TM,Park YW,Takemura S,et al.BLyS and APRIL in rheumatoid arthritis.J Clin Invest.2005,115:3083-3092.

共引文献124

同被引文献26

  • 1Anoop P.Immune thrombocytopenic purpura:historicalperspective,current status,recent advances and futuredirections[J].Indian Pediatr,2012,49(10):811-818.
  • 2Provan D,Stasi R,Newland AC,et al.International consensusreport on the investigation and management of primary immunethrombocytopenia[J].Blood,2010,115(2):168-186.
  • 3Neunert C? Lim W,Crowther M,et al.The American Societyof Hematology 2011 evidence-based practice guideline forimmune thrombocytopenia[J].Blood,2011,117(16):4190-4207.
  • 4Rodeghiero F,Ruggeri M.ITP and international guidelines:what do we know,what do we need?[J].Presse Med,2014,43(4):e61-e67.
  • 5Kojouri K,Vesely SK,Terrell DR,et al.Splenectomy for adultpatients with idiopathic thrombocytopenic purpura:a systematicreview to assess long-term platelet count responses,prediction ofresponse,and surgical complications[J].Blood,2004,104(9):2623-2634.
  • 6Mikhael J,Northridge K,Lindquist K,et al.Short-term andlong-term failure of laparoscopic splenectomy in adult immunethrombocytopenic purpura patients:a systematic review[J].AmJ Hematol,2009,84(11):743-748.
  • 7Mohamed SY,Abdel-Nabi I,Inam A,et al.Systemicthromboembolic complications after laparoscopic splenectomy foridiopathic thrombocytopenic purpura in comparison to opensurgery in the absence of anticoagulant prophylaxis[J],HematolOncol Stem Cell Ther,2010,3(2):71-77.
  • 8Dahyot-Fizelier C,Debaene B,Mimoz O,et al.Management ofinfection risk in asplenic patients[J].Ann Fr Anesth Reanim,2013,32(4):251-256.
  • 9Ghanima W,Godeau B,Cines DB,et al.How I treat immunethrombocytopenia:the choice between splenectomy or a medicaltherapy as a second-line treatment[J].Blood,2012,120(5):960-969.
  • 10Cheunq E,Liebman HA.Anti-D immunoglobulin in thetreatment of immune thrombocytopenia[J].Bioloqics,2009,3(6):57-62.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部